Trending NewsTrending NewsNYSE:ABBV AbbVie (ABBV) Stock Price, News & Analysis $190.34 +3.23 (+1.73%) Closing price 07/23/2025 03:59 PM EasternExtended Trading$189.86 -0.49 (-0.26%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About AbbVie Stock (NYSE:ABBV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AbbVie alerts:Sign Up Key Stats Today's Range$186.77▼$190.8050-Day Range$181.52▼$194.9652-Week Range$163.81▼$218.66Volume4.34 million shsAverage Volume6.30 million shsMarket Capitalization$336.22 billionP/E Ratio81.00Dividend Yield3.45%Price Target$211.29Consensus RatingModerate Buy Company Overview AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Read More AbbVie Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreABBV MarketRank™: AbbVie scored higher than 98% of companies evaluated by MarketBeat, and ranked 36th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 16 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageAbbVie has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AbbVie's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth13.57% Earnings GrowthEarnings for AbbVie are expected to grow by 13.57% in the coming year, from $12.31 to $13.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbbVie is 81.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.64.Price to Earnings Ratio vs. SectorThe P/E ratio of AbbVie is 81.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.08.Price to Earnings Growth RatioAbbVie has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAbbVie has a P/B Ratio of 100.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AbbVie's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.91% of the float of AbbVie has been sold short.Short Interest Ratio / Days to CoverAbbVie has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AbbVie has recently increased by 8.50%, indicating that investor sentiment is decreasing significantly. Dividend4.2 / 5Dividend StrengthStrong Dividend LeadershipAbbVie is a leading dividend payer. It pays a dividend yield of 3.51%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthAbbVie has been increasing its dividend for 53 years.Dividend CoverageThe dividend payout ratio of AbbVie is 279.15%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, AbbVie will have a dividend payout ratio of 46.92% next year. This indicates that AbbVie will be able to sustain or increase its dividend.Read more about AbbVie's dividend. Sustainability and ESG3.9 / 5Environmental Score-2.34 Percentage of Shares Shorted0.91% of the float of AbbVie has been sold short.Short Interest Ratio / Days to CoverAbbVie has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AbbVie has recently increased by 8.50%, indicating that investor sentiment is decreasing significantly. News and Social Media3.9 / 5News Sentiment0.98 News SentimentAbbVie has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 80 news articles for AbbVie this week, compared to 64 articles on an average week.Search Interest119 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 70% compared to the previous 30 days.MarketBeat Follows41 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 37% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AbbVie insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.25% of the stock of AbbVie is held by insiders.Percentage Held by Institutions70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbbVie's insider trading history. Receive ABBV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. Email Address ABBV Stock News HeadlinesAbbVie’s Promising Phase 3 Study: A Potential Game-Changer in Cancer TreatmentJuly 23 at 12:54 PM | tipranks.comAbbVie’s Pediatric Ulcerative Colitis Study: A Potential Market Game-ChangerJuly 22 at 12:47 PM | tipranks.comBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%. | Altimetry (Ad)AbbVie’s Pediatric IBS-D Study: A Potential Market Game-ChangerJuly 22 at 12:47 PM | tipranks.comAbbVie’s Promising Phase 3 Study on Lutikizumab for Hidradenitis SuppurativaJuly 22 at 12:47 PM | tipranks.comAbbVie’s New Study on CLL Retreatment: What Investors Need to KnowJuly 22 at 12:47 PM | tipranks.comAbbVie’s Promising Pediatric Atopic Dermatitis Study: Key Insights for InvestorsJuly 22 at 12:47 PM | tipranks.com4 Reasons To Buy AbbVieJuly 22 at 11:21 AM | seekingalpha.comSee More Headlines ABBV Stock Analysis - Frequently Asked Questions How have ABBV shares performed this year? AbbVie's stock was trading at $177.70 at the start of the year. Since then, ABBV shares have increased by 7.1% and is now trading at $190.3410. How were AbbVie's earnings last quarter? AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings data on Friday, April, 25th. The company reported $2.46 EPS for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. The business's quarterly revenue was up 8.4% on a year-over-year basis. Read the conference call transcript. Does AbbVie have any subsidiaries? AbbVie subsidiaries include these companies: Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and others. Who are AbbVie's major shareholders? AbbVie's top institutional investors include Assenagon Asset Management S.A. (0.25%), Robeco Institutional Asset Management B.V. (0.18%), Kingstone Capital Partners Texas LLC (0.18%) and Truist Financial Corp (0.12%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Robert A Michael, Nicholas Donoghoe, Jeffrey Ryan Stewart, Timothy J Richmond, Roxanne S Austin, Carrie C Strom, Elaine K Sorg, Scott T Reents, Perry C Siatis and Kevin K Buckbee. View institutional ownership trends. How do I buy shares of AbbVie? Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbbVie own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC). Company Calendar Record date for 5/15 Dividend4/15/2025Ex-Dividend for 5/15 Dividend4/15/2025Last Earnings4/25/2025Dividend Payable5/15/2025Record date for 8/15 Dividend7/15/2025Ex-Dividend for 8/15 Dividend7/15/2025Today7/23/2025Next Earnings (Estimated)7/31/2025Dividend Payable8/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Large Cap Pharma Sub-IndustryPharmaceuticals Current SymbolNYSE:ABBV CIK1551152 Webwww.abbvie.com Phone(847) 932-7900Fax302-655-5049Employees55,000Year Founded2013Price Target and Rating Average Price Target for AbbVie$211.29 High Price Target$250.00 Low Price Target$180.00 Potential Upside/Downside+11.0%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage27 Analysts Profitability EPS (Trailing Twelve Months)$2.35 Trailing P/E Ratio81.00 Forward P/E Ratio15.46 P/E Growth1.24Net Income$4.28 billion Net Margins7.31% Pretax Margin6.31% Return on Equity412.03% Return on Assets13.11% Debt Debt-to-Equity Ratio44.14 Current Ratio0.76 Quick Ratio0.64 Sales & Book Value Annual Sales$56.33 billion Price / Sales5.97 Cash Flow$15.19 per share Price / Cash Flow12.53 Book Value$1.90 per share Price / Book100.18Miscellaneous Outstanding Shares1,766,400,000Free Float1,761,987,000Market Cap$336.22 billion OptionableOptionable Beta0.48 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NYSE:ABBV) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredWhy Elon put $51 million into thisEvery major AI breakthrough comes with a catch: It burns through power like jet fuel. Now Google, Microsof...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.